Recent Updates
Recently added Catalysts

STI-5656

Phase 3

Covid19 | Small Molecules | Infectious Disease |Sorrento Therapeutics, Inc.|Trials Updated: Jan 18, 2023

STI-5656 development status

Highest phase Phase 3 run by Hangzhou ACEA Pharmaceutical Research Co., Ltd. (NCT03058094)
Phase scored for SRNEPhase 2
Registered trials 4 across 2 sponsors since Feb 2017

STI-5656 target and mechanism

ModalitySmall Molecules

Also known as abivertinib maleate, avitinib, AC0010, abivertinib

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials2
Total Enrollment492

FDA Designations

No designations recorded

STI-5656 clinical trials

STI-5656 · 2 trials · 2 indications

Phase 2 2
NCT04528667Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19Covid19
COMPLETED396 Analytics
NCT04440007Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19Covid-19
COMPLETED96 Analytics
PHASE2COMPLETED
Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19
Covid19Unlock trial analytics
PHASE2COMPLETED
Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19
Covid-19Unlock trial analytics

Study Endpoints

Primary Endpoints

Proportion of subjects discharged from hospital
Randomization through Day 29

Proportion of subjects whoa re alive and discharged from the hospital by Day 29

Percentage of Subjects Alive and Free of Respiratory Failure at Day 28
Randomization to Day 28

Percentage of subjects alive and free of respiratory failure at Day 28, where respiratory failure, is defined based on resource utilization of any of the following modalities: * Noninvasive positive pressure ventilation or continuous positive airway pressure * Endotracheal intubation and mechanical ventilation * Oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates \>20L/min with fraction of delivered oxygen ≥ 0.5) * Extracorporeal membrane oxygenation

Secondary Endpoints

Incidence of adverse events (safety)
Randomization through study completion through Day 36
Time to hospital admission, treatment, and discharge
Randomization through study completion through Day 36
Number of days hospitalized
Randomization to Day 36
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
STI-5656EXPERIMENTALSTI-5656 (abivertinib maleate) capsules administered orally 100 mg QD for 7 days, in addition to standard of care
PlaceboPLACEBO_COMPARATORPlacebo capsules administered orally daily for 7 days, in addition to standard of care
Abivertinib with Standard of CareEXPERIMENTALSTI-5656 (abivertinib maleate) capsule administered orally 200 mg QD up to 28 days or until hospital discharge, in addition to standard of care
Standard of CareACTIVE_COMPARATORStandard of care treatments for COVID-19 as determined appropriate by the Investigator

Interventions

NameTypeDescription
STI-5656DRUGSTI-5656 (abivertinib maleate) is a third-generation EGFR tyrosine kinase inhibitor and BTK Inhibitor.
PlaceboDRUGPlacebo capsules
AbivertinibDRUGAbivertinib maleate is a third-generation EGFR tyrosine kinase inhibitor and BTK Inhibitor. The starting dose is 200 mg p.o. QD for up to 28 days.
Standard of CareOTHERStandard of Care as determined by the Investigator
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Confirmed positive for COVID-19 by RT-PCR assay or equivalent * Subject or family member/caregiver must have provided written informed consent which includes signing the institutional review board (IRB) or independent ethics committee (IEC) approved consent form prior to parti...

Countries:BrazilUnited States
Unlock Eligibility Criteria